PLOS ONE

Efficacy and effectiveness of SARS-CoV-2 vaccines for death prevention: A protocol for a systematic review and meta-analysis

Anete Trajman[1,2☯]*, Sophie Lachapelle-Chisholm[1☯]*, Théodora Zikos[3☯], Guilherme Loureiro Werneck[4,5‡], Andrea Benedetti[1‡]

1 Research Institute, McGill University Health Center, Montréal, QC, Canada, 2 Faculdade de Medicina, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 3 Institut National d'Excellence en Santé et en Services Sociaux, Montreal, QC, Canada, 4 Instituto de Medicina Social Hesio Cordeiro, State University of Rio de Janeiro, Rio de Janeiro, Brazil, 5 Instituto de Estudos de Saúde Coletiva, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

☯ These authors contributed equally to this work.
‡ LW and AB also contributed equally to this work.
* sophie.lachapelle-chisholm@rimuhc.ca (SLC); anete.trajman@medicina.ufrj (AT)

Abstract

Background

There is consistent evidence that SARS-CoV-2 vaccines have statistical and clinical significant efficacy to prevent incident and severe cases of COVID-19, although different outcomes were analyzed and different risk reductions were observed. However, randomized control trials (RCT) were not designed or powered to assess whether the vaccines prevent deaths, even though this was a secondary or exploratory outcome across many studies. Early real-world observational data suggest that these vaccines are highly effective in reducing hospitalization and all-cause mortality. Our objective is to summarize and appraise—the existing evidence on the efficacy and real-world effectiveness of all SARS-CoV-2 vaccines currently approved for full or limited use to prevent all-cause and COVID-19-attributed mortality.

Methods

The **population** consists of persons with a record of vaccination status and the outcome of interest. Randomized controlled trials, comparative cohort and case-control studies reporting vaccination with any of the vaccines approved (**intervention**) will be eligible. The primary **outcome** will be all cause deaths. COVID-19-attributed deaths and deaths attributable to the vaccination (adverse event deaths) will be secondary outcomes. We will **compare** deaths occurring in vaccinated persons versus those non-vaccinated or having received placebo. Studies in any language will be eligible. Two independent reviewers will screen for inclusion and assess quality of studies using the Cochrane Risk of Bias 2 and the ROBINS-1 tool, as appropriate. Hazard ratios will be calculated. Assessment of statistical heterogeneity amongst the studies will be done using I^2 and prediction intervals, as well as visual inspection of the forest plots. Publication bias will be assessed using a funnel plot and

Egger statistical test if we have more than 10 studies in a forest plot. We have followed the PRISMA-Protocol checklist for the current protocol, which is registered at Prospero (York University, CRD42021262211).

Background

The emergence of human infection with SARS-CoV-2 was first observed in late 2019, when cases of unexplained pneumonia were reported in Wuhan, China [1]. The human disease caused by SARS-CoV-2 is known as COVID-19. The World Health Organization (WHO) declared a COVID-19 pandemic on March 11th, 2020. Successive waves of high transmission and the emergence of new variants in several countries ensued [2]. As of January 6th, 2022, 5,462,631 deaths from COVID-19 had been reported worldwide, though this is likely an underestimation [3]. COVID-19 is thus the leading cause of death from an infectious disease worldwide.

In contrast with the multi-year long developmental process of previous vaccines, less than a year after the SARS-CoV-2 genome sequence was described on January 10th, 2020 [4], new vaccines have already been developed. Using different technologies, these vaccines have been tested for safety and efficacy in preventing SARS-CoV-2 infection and hospitalization, with the first vaccine having been implemented as early as December 20th, 2020 [5]. Currently, there are 27 vaccines undergoing Phase I safety trials, 30 undergoing combined Phase I and II trials, 9 undergoing expanded safety Phase II trials, 10 undergoing combined Phase II and III trials, 36 undergoing large scale efficacy Phase III trials, 9 undergoing Phase IV trials, with 23 vaccines approved for full use by several regulatory agencies [6]. In addition, 9 vaccines have been abandoned [7].

In a scoping review, we found that there is consistent evidence that SARS-CoV-2 vaccines —whichever the employed technology—have statistical and clinical significant efficacy to prevent cases of COVID-19, although different outcomes were analyzed and different risk reductions were observed [8–12]. However, these randomized control trials (RCT) were not designed or powered to assess whether the vaccines prevented deaths, even though this was a secondary or exploratory outcome across many studies. When isolated, none of these RCT had the power to ascertain whether the risk of death was reduced by the intervention.

Early observational data from different populations and settings in which the vaccines have been implemented have shown that vaccines are highly effective in reducing hospitalization and all-cause mortality [5, 11–17]. (5,–However, along with the intrinsic limitations with observational studies, some researchers have used an ecological design [18], which has led to quality of evidence that is heterogeneous. Important possible biases found with observational studies of vaccine effectiveness include confounding due to healthcare-seeking behaviour, exposure risk, misclassification of outcomes due to diagnostic errors, prior SARS-CoV-2 infection, and spurious inferences of waning [19]. Despite these limitations, the WHO recommends performing vaccine effectiveness observational studies to better understand the impact of large-scale vaccination on COVID-19 mortality, as RCTs have limited evidence [19]. These studies, according to the WHO, can have a high impact for public health decision-makers [19].

No systematic reviews on the efficacy and effectiveness of SARS-CoV-2 vaccines for preventing all-cause mortality were found in our scoping review. One published systematic review evaluated safety and surrogates of efficacy such as neutralizing antibodies, but mortality was not one of the endpoints [20]. We found seven registered ongoing systematic review protocols on the safety and efficacy of SARS-CoV-2 vaccines. One [21] will evaluate prevention of any

form of SARS-CoV-2 infection as the efficacy outcome and will only include evidence from single- or double-blinded control trials. The second will be a living mapping of research and network meta-analysis of multiple interventions to prevent the spreading of the disease [22]. Another living systematic review will analyze efficacy endpoints including death, but only observational studies will be included for adverse event analyses [23]. And another systematic review and network meta-analysis will attempt to compare the efficacy, effectiveness and safety of various COVID-19 vaccines using data from RCT studies and COVID-19 death will be one of the main outcomes [24]. Thus, pooled efficacy and real-world effectiveness of SARS-CoV-2 vaccination for all-cause mortality is not yet being evaluated.

Our objective is to summarize and appraise—and, if possible, pool—the existing evidence on the efficacy and real-world effectiveness of all SARS-CoV-2 vaccines currently approved for use for the prevention of all-cause and COVID-19-attributed mortality. We intend to do so by including RCTs, as well as cohort and case-control studies in our review. We hypothesize that the summarized data will suggest an association between vaccine use and a reduction of all-cause mortality.

Objectives

The following PICO question will guide our methods: Compared to the non-vaccinated (or placebo-vaccinated) population, what is the efficacy and effectiveness of the currently available for use SARS-CoV-2 vaccines on all-cause mortality among individuals aged 12 years or over, in any setting worldwide, as of the first day of the first dose received?

- Disease: PCR-Rt or viral culture confirmed SARS-CoV-2 infection/COVID-19.

- Population: persons over 12 years old.

- Settings: all settings included (both high-(HIC) and low- and medium-income countries (LMIC), community, short and long-term care, remote, hospital settings).

- Interventions: any SARS-CoV-2 vaccination currently available for use in any country (26vaccines using varying technologies have been approved for full use in at least one country by several regulatory agencies as of 4 December 2021, see Appendix I in S1 Appendix).

- Comparators: non exposure to SARS-CoV-2 vaccination, placebo.

- Outcome: Primary outcome is all-cause mortality after 1st dose of vaccination, and 2nd dose of vaccination, if reported. The reasons for this choice are the imprecision of attribution of deaths to COVID-19, especially in LMIC [3]. Secondary outcomes are COVID-confirmed deaths, and death as an adverse event (AE) of the intervention.

- Time: from date of 1st or 2nd dose of vaccine administered until 12 months thereafter or last follow-up available.

- Study Designs: RCT (phases I, II or III) and cohort studies. Ecological studies will be excluded, and case-control studies may be included in an exploratory analysis.

Methods

We will follow Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) and have followed the PRISMA-Protocol checklist for the current protocol, see S1 Checklist [25, 26].

Eligibility criteria

Studies will be selected according to the criteria outlined below.

Study designs. We will include RCTs, as well as prospective and retrospective comparative cohort studies. Cohorts with one single arm, and ecological studies will be excluded. Case-control studies will be assessed for pertinent design and validity, and may be included in an additional exploratory analysis.

Participants. Studies involving patients aged 12 years and older in any country for whom we have vaccination and outcome information are eligible. We will include studies addressing specific or vulnerable populations. The intervention population will include patients who have received a vaccine of any form.

Interventions. The interventions of interest are treatment with any SARS-CoV-2 vaccine approved for use in any country, or completed phase III RCT SARS-CoV-2 vaccine authorized for limited use in any country. A list of vaccines that are currently in either category is provided in Appendix I in S1 Appendix.

Comparators. The comparators are either patients receiving a placebo, or participants with no exposure to a SARS-CoV-2 vaccination.

Outcomes. There are three outcomes of interest:

1. All-cause mortality (our primary outcome) after the first dose of vaccine, and second dose when reported, whether primary or secondary outcome in original study.

2. COVID-related death (our secondary outcome), whether primary or secondary outcome in original study 14 days after the immunization regimen is complete.

3. Death as an AE after intervention (our secondary outcome), whether primary or secondary outcome in original study from the date of the first dose.

All-cause mortality will encompass all deaths, regardless of cause. COVID-related death will be defined as a participant with a cause of death directly attributable to COVID-19 or a complication thereof as defined by the WHO International Guidelines for Certification and Classification (CODING) of COVID-19 as cause of death. Death as an adverse event will be defined as any death related to the intervention as defined by the WHO COVID-19 Vaccines safety Surveillance Manual [27] and The Global Manual on Surveillance of Adverse Events Following Immunization [28]. Definitions of fatal adverse events will be documented for each study during the data extraction phase. All deaths occurring within one, two, and three months of the first or second dose will be reviewed to determine whether it is considered an AE.

We will include studies with any measures of effect and calculate hazard ratios.

Timing. We will include all studies regardless of follow-up duration. Primary outcome will be all-cause mortality up to 12 months following the first vaccination dose, and second vaccination dose when reported, starting from the date of vaccination. For COVID-related death, the timeframe will begin at 2 weeks following the completed regimen and end 12 months later, or until the last follow-up. Death as an AE will be limited to three months following the vaccination, starting from the date of the first dose, or from the second dose if documented. We will extract information by month (1st, 2nd, and 3rd) after the first dose or, when available, the second dose or booster shot. These timeframes may be modified if found to be incompatible with most articles being reviewed.

Setting. There will be no restrictions by type of setting.

Language. As excluding languages could ignore key data and potentially introduce bias, we will include relevant articles reported in any language for which we have a translator. Those relevant titles we cannot translate will be provided as an S1 Appendix.

Search strategy

We will invite a health sciences librarian with experience conducting systematic review searches to aid in the refinement of our strategy. In conjunction with a librarian, we will develop a literature search strategy employing both medical subject headings (MeSH) and text words related to and synonymous with COVID-19, SARS-CoV-2, vaccines, immunotherapy, death, adverse event, treatment outcome, efficacy, effectiveness. The following databases will be searched: Ovid MEDLINE, Embase, PubMed, Web of Science, LILACS and the WHO Global research for COVID-19 database. We will also search for clinical trials and currently in-progress research via: ClinicalTrials.gov, Ovid MEDLINE In-Progress and Other Non-Indexed Citations, EudraCT, Cochrane Library and COVID-19 Study Register, COVID-19 Vaccine Trials (https://covid19vaccinetrial.co.uk/), and medRxiv. The online database search will be supplemented with relevant articles found in the reference lists of eligible articles and pertinent reviews. Grey literature will also be consulted, including searching regulatory and reporting agencies (European Medicines Agency, Pharmaceutical Safety and Efficacy Assessment Report, CDC, WHO), and sponsors and developers will be contacted when deemed appropriate.

Based on a preliminary search of relevant articles conducted by the authors, we developed a systematic search strategy based on various synonyms for the keywords above. We have included the draft search strategy as Appendix II in S1 Appendix. Following completion of the initial search strategy, we will adapt the syntax according to the specific functions of each subsequent database. As research in this field is limited but growing, and we are including observational and controlled studies, our goal is to maximize the sensitivity and broadness of our search. To this end, the search strategy will not include study design filters or population parameters, nor will it exclude any date ranges. In addition, we propose both a provision for repeating searches towards the end of the review process, as well as initiating current awareness alerts.

Once the search strategy is established, one reviewer (SLC) will conduct the search and documentation. The PRISMA-S 16-item checklist for reporting search strategies will be followed. EndNote software will be used for citation management.

Study selection

Abstracts and titles yielded from the database searches will be uploaded to the free web tool Rayyan to facilitate the screening and selecting of titles. To avoid potential bias stemming from duplicate study inclusion, the reviewers will cross-reference author names as well as juxtapose sample sizes, treatments, and outcomes. Full texts will be handled with the citation software EndNote. Two independent reviewers (SLC and TZ) will conduct the initial screening for inclusion, adhering to predetermined eligibility criteria. If one reviewer deems the article eligible, both reviewers will examine the full text. A PRISMA flow diagram will be created following the screening process. During the full text review phase, the independent reviewers will decide on eligibility. A third independent reviewer (AT) will resolve disagreements. If more data is necessary for a decision, article authors will be contacted. Only if there is consensus on an article's eligibility will data be extracted. Reasons for exclusion will be recorded. We will not blind reviewers to authors and journals.

Data extraction

We will develop a standardized electronic data extraction form tailored to our review. Prior to extracting data, the form will be piloted on 10 articles by two independent reviewers (SLC and TZ) to ensure the form consistently captures all relevant data. Forms will be calibrated as

necessary. Data extraction will occur in duplicate by the two reviewers. A third reviewer (AT) will arbitrate to resolve disagreements. Article authors will be contacted if there remains uncertainty about data.

Data to be extracted will consist broadly of general study information, study characteristics, patient characteristics, intervention and COVID-related data, outcome/results, and additional information not previously classified. We will also take note of the study period to check for the epidemiological situation in the country (background risk of disease and death, variants of concern). If not reported in the original study this will be verified in publicly available statistics. A precursory listing of data we intend to extract is included as Appendix III in S1 Appendix. While this list is based on data we expect to find based on available checklists and preliminary articles reviewed, it is not exhaustive. We will modify the form where necessary after the search is completed, and prior to beginning data extraction. One data extraction form will be used for all articles included.

Assessment of methodological quality

Two reviewers (AT and TZ) will independently perform the quality assessment, with any discrepancy being resolved by a third reviewer (GLW). The agreement between reviewers will be expressed as a percentage. The assessment will be blinded for the third reviewer. The reviewers will use two separate tools to assess risk of bias, depending on study design. For the RCTs, we will use the Cochrane Risk of Bias 2 tool [29]. We will assess risk of bias according to the following domains: random sequence generation, allocation concealment, blinding (subjects, personnel, outcome assessment), incomplete outcome data, selective outcome reporting, and source of funding [30].

Quality of observational studies will be assessed using the ROBINS-1 tool [30]. We will evaluate risk of bias due to confounding, selection, interventions (classification/deviations), missing data, measurement of outcomes and selection of the reported result. The confounders will be determined based on the WHO's interim guidance on assessing COVID-19 vaccine effectiveness using observational study designs [19]. As such, we are expecting to consider exposure and background risk (including variants of concern circulating in each setting), prior SARS-CoV-2 infection, health care seeking behavior, risk reduction behavior, healthcare access, age, sex, comorbidities, and time since vaccination amongst others. An emphasis will be placed on age and background risk—including variants of concern—in our discussion.

We will judge each potential source of bias as high, low, or unclear and provide justification for our judgement.

Sensitivity analyses will be done excluding low-quality studies in scenario 1. In a second scenario, we will explore how low-quality studies would have affected the results.

The certainty of evidence will be rated using the GRADE approach (considering risk of bias, consistency of effect, imprecision, indirectness, and publication bias) [30].

Data analysis

We will pool RCT and observational studies separately in our primary analysis and, if possible, altogether in secondary analyses. Case-control studies will be examined in an exploratory analysis. We will analyze data as hazard ratio (HR) providing 95% confidence intervals (CI) for the results under a proportional hazards model for the exposure. The effect of vaccination on all-cause mortality as well as secondary outcomes will be expressed as (1-HR). HR will be calculated, when possible, using the methods described by Tierney [31]. If multiple studies are found reporting risk ratios (RR) and odds ratios (OR) instead of HR, RR and OR will be converted to HR using the methods described by VanderWeele [32].

We will not adjust HR in RCT. Adjusted values will be used in observational studies if appropriate and if the same confounders and methods of adjustment are found across studies. Additionally, we will consider a sensitivity analysis using adjusted values based on the study-specific adjustments. We will preferably use age adjustments. If there are many null values, the approach outlined by Negeri et al. will be applied [33]. We will assess clinical, methodological, and statistical heterogeneity. Assessment of statistical heterogeneity amongst the studies will be done using I^2 and prediction intervals, as well as visual inspection of the forest plots. The following thresholds will be used for the I^2 test:

0% to <30%: might not be important;

30% to <50%: may represent moderate heterogeneity;

50% to <75%: may represent substantial heterogeneity;

75% to 100%: considerable heterogeneity [25].

We will investigate the sources of heterogeneity if the threshold of 75% has been crossed. If considerable heterogeneity is found, we will use a narrative approach towards data synthesis. If studies are found to be homogeneous, a meta-analysis for each study design (RCT/cohort) will be done using the Meta package of the R studio software. When feasible, we will perform pre-specified subgroup analyses according to type of vaccine (mRNA, viral vector, inactivated, protein subunit) and study country. In addition, we will perform a meta-regression if enough power and sufficient data are available for the following variables of potential interest: age, sex, time since latest dose, number of doses, vaccine type, variants circulating and availability to of viral gene sequencing in the country, previous SARS-CoV-2 infection, comorbidities, exposure and background risk, health care seeking behavior, risk reduction behavior, healthcare access, and setting (community, long-term care, hospital). If we are unable to do so we will prioritize meta-regression for age, number of doses, time since latest dose, variants of concern, and background risk. A similar approach will be undertaken in our exploratory analysis of case-control studies.

As we expect to find clinical and statistical heterogeneity, we will use a random-effects model using the Der Simonian & Laird method in our primary analysis. A fixed-effect model (Mantel-Haenszel method) will be used as a sensitivity analysis.

Publication bias will be assessed using a funnel plot and Egger statistical test if we have more than 10 studies in a forest plot.

Finally, we plan to conduct the review according to this protocol but will report any deviations. Reporting of the review will follow PRISMA-2020 guidelines [34].

The protocol is registered at Prospero (York University), # CRD42021262211.

Supporting information

S1 Checklist. PRISMA-P 2015 checklist.
(PDF)

S1 Appendix. Appendices I, II, III.
(DOCX)

Acknowledgments

Author Contributions

Conceptualization: Anete Trajman, Sophie Lachapelle-Chisholm, Théodora Zikos.

Data curation: Sophie Lachapelle-Chisholm.

Formal analysis: Théodora Zikos, Andrea Benedetti.

Investigation: Sophie Lachapelle-Chisholm.

Methodology: Anete Trajman, Théodora Zikos, Guilherme Loureiro Werneck, Andrea Benedetti.

Writing – original draft: Anete Trajman, Sophie Lachapelle-Chisholm, Théodora Zikos.

Writing – review & editing: Anete Trajman, Sophie Lachapelle-Chisholm, Théodora Zikos, Guilherme Loureiro Werneck, Andrea Benedetti.

References

1. WHO-convened global study of origins of SARS-CoV-2: China Part [Internet]. [cited 2021 May 15]. Available from: https://www.who.int/publications-detail-redirect/who-convened-global-study-of-origins-of-sars-cov-2-china-part

2. Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. J Basic Microbiol. 2021 Mar; 61(3):180–202. https://doi.org/10.1002/jobm.202000537 PMID: 33460172

3. Kung S, Doppen M, Black M, Braithwaite I, Kearns C, Weatherall M, et al. Underestimation of COVID-19 mortality during the pandemic. ERJ Open Res [Internet]. 2021 Feb 15 [cited 2021 May 15]; 7(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734715/ https://doi.org/10.1183/23120541.00766-2020 PMID: 33614772

4. Holmes EC. Novel 2019 coronavirus genome—SARS-CoV-2 coronavirus [Internet]. Virological. 2020 [cited 2021 May 15]. Available from: https://virological.org/t/novel-2019-coronavirus-genome/319

5. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021 May 15; 397(10287):1819–29.

6. COVID-19 vaccine tracker [Internet]. [cited 2022 Jan 4]. Available from: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/

7. WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2021 Jun 18]. Available from: https://covid19.who.int

8. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4; 384(5):403–16. https://doi.org/10.1056/NEJMoa2035389 PMID: 33378609

9. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet. 2021 Apr 10; 397(10282):1351–62. https://doi.org/10.1016/S0140-6736(21)00628-0 PMID: 33798499

10. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20; 397 (10275):671–81. https://doi.org/10.1016/S0140-6736(21)00234-8 PMID: 33545094

11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31; 383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577 PMID: 33301246

12. Ledford H. Six months of COVID vaccines: what 1.7 billion doses have taught scientists. Nature. 2021 Jun 4; 594(7862):164–7. https://doi.org/10.1038/d41586-021-01505-x PMID: 34089016

13. Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England [Internet]. Infectious Diseases (except HIV/AIDS); 2021 Mar [cited 2021 May 15]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.03.01.21252652

14. Britton A. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks—Connecticut, December 2020–February 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2021 May 15]; 70. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7011e3.htm

15. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021 Apr 15; 384(15):1412–23. https://doi.org/10.1056/NEJMoa2101765 PMID: 33626250

16. Moustsen-Helms IR, Emborg H-D, Nielsen J, Nielsen KF, Krause TG, Mølbak K, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers–a Danish cohort study | medRxiv [Internet]. [cited 2021 May 15]. Available from: https://www.medrxiv.org/content/10.1101/2021.03.08.21252200v1

17. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet. 2021 May 1; 397(10285):1646–57. https://doi.org/10.1016/S0140-6736(21)00677-2 PMID: 33901420

18. Victora C, Castro MC, Gurzenda S, Barros AJD. Estimating the early impact of immunization against COVID-19 on deaths among elderly people in Brazil: analyses of secondary data on vaccine coverage and mortality. medRxiv. 2021 Apr 30;2021.04.27.21256187.

19. WHO. Evaluation of COVID-19 vaccine effectiveness. Interim guidance. C BY-NC-SA 3.0 IGO [Internet]. [cited 2021 May 15]. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1

20. Xing K, Tu X-Y, Liu M, Liang Z-W, Chen J-N, Li J-J, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021 Mar; 23(3):221–8. https://doi.org/10.7499/j.issn.1008-8830.2101133 PMID: 33691913

21. Simon A, Adera T, Yilma T, Sawadogo W. A systematic review and meta-analysis of the safety and efficacy of SARS-CoV-2 vaccines currently available for use. [Internet]. Prospero 2021. CRD42021244994. 2021 [cited 2021 May 14]. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=244994

22. Boutron I, Chaimani A, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, et al. Interventions for the prevention and treatment of COVID-19: a living mapping of research and living network meta-analysis. Cochrane Database of Systematic Reviews [Internet]. 2020 [cited 2021 May 14];(11). Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013769/full?highlightAbstract=19%7Ccovid

23. Korang SK, Juul S, Nielsen EE, Feinberg J, Siddiqui F, Ong G, et al. Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project). Systematic Reviews. 2020 Nov 20; 9(1):262. https://doi.org/10.1186/s13643-020-01516-1 PMID: 33218366

24. Li Q, Wu J. Efficacy, effectiveness, and safety of COVID-19 vaccines in adults: a systematic review and network meta-analysis. PROSPERO 2021 CRD42021261600 [Internet]. [cited 2021 Jun 19]. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021261600

25. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1; 4:1. https://doi.org/10.1186/2046-4053-4-1 PMID: 25554246

26. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2; 350:g7647. https://doi.org/10.1136/bmj.g7647 PMID: 25555855

27. WHO. COVID-19 Vaccines: Safety Surveillance Manual. Module: Establishing active surveillance systems for adverse events of special interest during COVID-19 vaccine introduction [Internet]. [cited 2021 Jun 19]. Available from: https://www.who.int/vaccine_safety/committee/Module_AESI.pdf?ua=1

28. Amarasinghe A, World Health Organization, Global Advisory Committee on Vaccine Safety. Global manual on surveillance of adverse events following immunization [Internet]. 2016 [cited 2021 Jun 10]. Available from: http://apps.who.int/iris/bitstream/10665/206144/1/9789241507769_eng.pdf

29. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18; 343:d5928. https://doi.org/10.1136/bmj.d5928 PMID: 22008217

30. Higgins JPT, Cochrane Collaboration, editors. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Second edition. Hoboken, NJ: Wiley-Blackwell; 2021. (Cochrane book series).

31. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007 Jun 7; 8(1):16. https://doi.org/10.1186/1745-6215-8-16 PMID: 17555582

32. VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to risk ratios. Biometrics. 2020; 76(3):746–52. https://doi.org/10.1111/biom.13197 PMID: 31808145

33. Negeri ZF, Shaikh M, Beyene J. Bivariate random-effects meta-analysis models for diagnostic test accuracy studies using arcsine-based transformations. Biometrical Journal. 2018; 60(4):827–44. https://doi.org/10.1002/bimj.201700101 PMID: 29748967

34. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29; 372:n71. https://doi.org/10.1136/bmj.n71 PMID: 33782057